Immuno-Oncology | Specialty

Dr. Balmanoukian on Immunotherapy Advancements in GU Cancers

March 5th 2018

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.

Research Strategies to Improve Outcomes in GBM

March 5th 2018

GBM Emerging Strategies in Immunotherapy

March 5th 2018

GBM Rationale for Combining PD1 Inhibitor DNA Vaccine

March 5th 2018

PD1 Inhibitor DNA Vaccine Combination Trial in GBM

March 5th 2018

DNA Vaccine Creating Immunogenicity in GBM

March 5th 2018

Efficacy of Checkpoint Inhibition in Glioblastoma

March 5th 2018

Challenges With Immunotherapy in Glioblastoma

March 5th 2018

Spigel Reflects on Recent Immunotherapy Success in Stage III NSCLC

March 2nd 2018

David R. Spigel, MD, discusses the status of immunotherapy in locally advanced NSCLC and highlights recent milestones.

DDR Alterations Associated With Increased Anti-PD-1/PD-L1 Activity in Bladder Cancer

March 2nd 2018

Alterations in DNA damage response and repair genes were associated with an increased response to anti-PD-1/PD-L1 antibodies in patients with metastatic urothelial carcinoma.

Optimizing Immunotherapy in Lung Cancer

March 1st 2018

Claude Denham, MD, discusses the challenges with immunotherapy in NSCLC cancer, as well as the promise of combination therapy.

Limitations in the Management of NETs

March 1st 2018

Developments in the NETs Treatment Landscape

March 1st 2018

Role of PRRT in the Management of NETs

March 1st 2018

Deciding on SSA Treatment in NETs

March 1st 2018

Overview of Somatostatin Analogs for NETs

March 1st 2018

Symptom Control in Functional NETs

March 1st 2018

Risk Stratification and Management of NETs

March 1st 2018

Surgical Considerations for Neuroendocrine Tumors

March 1st 2018

Advances in the Management of NETs

March 1st 2018